Immunomedics: Short-Term Risk, Long-Term Opportunity

6/14/18

By William Meyers, SeekingAlpha

Immunomedics (NASDAQ:IMMU) is a clinical-stage biotech pharmaceutical company specializing in cancer therapies. A market cap near $4.2 billion shows a tremendous amount of optimism about the company's leading drug candidate. The key question at this point is whether the submission of available data to the FDA will result in an early approval, or whether a Phase 3 trial will be necessary. The current market cap seems to assume approval, so the short-term risk is to the downside. Longer term, successful label expansion or pipeline development could justify the stock moving upward. Expect some volatility until an FDA decision is handed down. On June 11, 2018, IMMU closed at $23.83, near its 52-week high of $26.48 and 232% up from its 52-week low of $7.17.

ChartIMMU data by YCharts

Immunomedics has an extensive pipeline, but most of the near-term value is in its lead candidate, Sacituzumab Govitecan for breast cancer. Here's the chart from the Immunomedics pipeline page:

READ FULL ARTICLE HERE